# US 2025/0154455 A1 · Bioactive and antioxidant supramolecular polymer hydrogels for neural cell culture

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154455 A1
- Document ID: US20250154455A1
- Status: Published application
- Kind: A1
- Application number: 18/941,862
- Filed: 2024-11-08
- Published: 2025-05-15
- Earliest claimed: 2023-11-10
- Assignees: Northwestern University
- Applicants: Northwestern University
- Inventors: Nicholas A. Sather; Bo Timmy Bjoern Fyrner; Samuel Isaac Stupp; Anna Metlushko
- Web page: https://patentgrep.com/patent/US20250154455A1

## CPC

- C12N 5/0619: {Neurons}
- C12M 25/02: {Membranes; Filters (filters or filtration in general B01D24/00-B01D41/00)}
- C12N 2513/00: 3D culture
- C12N 2533/30: Synthetic polymers
- C12N 2533/50: Proteins
- C12N 2537/10: Cross-linking
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}

## Abstract

Provided herein are compositions comprising a copolymer comprising at least one sulfonatoalkoxy EDOT monomer (e.g. EDOT-S) or at least one cationic EDOT monomer and at least one heterocyclic monomer (e.g. an EDOT-OH monomer) and one or more bioactive peptide amphiphiles (PAs). The compositions provided herein find use in cell culture methods and in methods of promoting neural growth and maturation.

## Claims

### Claim 1

A copolymer comprising (i) at least one sulfonatoalkoxy EDOT monomer or at least one cationic EDOT monomer, and (ii) and at least one heterocyclic monomer.

### Claim 2 (depends on 1)

The copolymer of claim 1, wherein the at least one sulfonatoalkoxy EDOT monomer comprises EDOT-S or wherein the at least one cationic EDOT monomer comprises an EDOT imidazolium monomer.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The copolymer of claim 1, wherein the at least one heterocyclic monomer comprises at least one thiophene monomer.

### Claim 5 (depends on 4)

The copolymer of claim 4, wherein the at least one heterocyclic monomer comprises at least one EDOT monomer.

### Claim 6 (depends on 5)

The copolymer of claim 5, wherein the at least one EDOT monomer is functionalized with a hydroxyl group or a N-methylimidazole group.

### Claim 7 (depends on 1)

The copolymer of claim 1, wherein the at least one heterocyclic monomer is an EDOT-OH monomer.

### Claim 8 (depends on 1)

The copolymer of claim 1, comprising the at least one sulfonatoalkoxy EDOT monomer or at least one cationic EDOT monomer, and the least one heterocyclic monomer at a ratio of 1:10 to 10:1.

### Claim 9 (depends on 8)

The copolymer of claim 8, comprising the at least one sulfonatoalkoxy EDOT monomer or at least one cationic EDOT monomer, and the at least one heterocyclic monomer at a ratio of 4:1.

### Claim 10 (depends on 1)

A composition comprising the copolymer of claim 1 and a hydrogel material.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the copolymer is directly linked to the hydrogel material, or wherein the composition further comprises a linker that covalently or noncovalently links the copolymer to the hydrogel material.

### Claim 12 (depends on 11)

The composition of claim 11, wherein leakage of the copolymer from the hydrogel is less than 10%, less than 5%, less than 2%, or less than 1% over the course of 7 days.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the hydrogel material comprises a polysaccharide.

### Claim 14 (depends on 10)

The composition of claim 10, wherein the hydrogel material comprises a plurality of bioactive peptide amphiphiles, each bioactive peptide amphiphile comprising a hydrophobic tail, a structural peptide segment, a charged peptide segment, and a bioactive moiety.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the hydrophobic tail comprises an 8-24 carbon alkyl chain (C8-24), the structural peptide segment has a total propensity for forming β-sheet conformation of 4 or less, the charged peptide segment comprises EE, EEE, or EEEE (SEQ ID NO: 3), the bioactive moiety comprises IKVAV (SEQ ID NO: 1), and/or the bioactive moiety is attached to the charged peptide segment by a linker.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

The composition of claim 15, wherein the structural peptide segment comprises A2G2(SEQ ID NO: 2).

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 15)

The composition of claim 15, wherein the linker is a single glycine (G) residue.

### Claim 22 (depends on 14)

The composition of claim 14, wherein the composition comprises a plurality of bioactive peptide amphiphiles comprising C8-24-A2G2E4GIKVAV (SEQ ID NO: 11).

### Claim 23 (depends on 14)

The composition of claim 14, further comprising one or more filler peptide amphiphiles, wherein the filler peptide amphiphiles comprise a hydrophobic non-peptide tail, a structural peptide segment, and a charged peptide segment, and do not comprise a bioactive moiety.

### Claim 24 (depends on 10)

A method comprising contacting a cell or a subject with the composition of claim 10.

### Claim 25

(canceled)

### Claim 26 (depends on 10)

A system comprising a cell cultured on the composition of claim 10.

### Claim 27

(canceled)

### Claim 28

(canceled)
